Convergent recombination-derived hepatocellular carcinoma-specific tcrs and applications thereof
Patent Information
- Application Number
- HK62026125928
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-07
- Filing Date
- 2026-07-09
- Publication Date
- 2026-09-11
Smart Images

Figure 00000060_0000 
Figure 00000060_0001 
Figure 00000060_0002
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480044723.3 (22) Application Date 2024.07.05 (30) Priority Data 63 / 512,299 2023.07.07 US (85) PCT International Application Entering National Phase Date 2025.12.30 (86) PCT International Application Application Data PCT / CN2024 / 103982 2024.07.05 (87) PCT International Application Publication Data WO2025 / 011485 EN 2025.01.16 (71) Applicant: University of Hong Kong Address: Pok Fu Lam Road, Hong Kong Applicant: Cancer and Immunology Research Centre Limited University Health Network (72) Inventors: Mai Dehua, Zheng Chunxing (74) Patent Agency: Beijing Liu Shen Law Firm 11105 Patent Attorney Mou Ke (51) Int.Cl. C07K 14 / 725 (2006.01) G01N 33 / 68 (2006.01) A61K 39 / 00 (2006.01) A61P 35 / 00 (2006.01) G01N 33 / 575 (2026.01) (54) Invention Title Convergent Recombinant Derivative Hepatocellular Carcinoma-Specific TCR and Its Application (57) Abstract T cell receptors (TCRs) play a crucial role in adaptive immune responses by recognizing specific antigens. In the context of cancer immunotherapy, TCR sequences can be engineered to target specific tumor antigens. In this study, hepatocellular carcinoma (HCC) was simulated in mice by combining genetic alterations repeatedly observed in human diseases, and HCC-specific TCRs were identified using single-cell TCR-seq. TCR convergence was observed in mice carrying HCC, indicating that HCC antigen-specific TCRs induce CD4+ T cell expansion. To further elucidate the function of this HCC-specific TCR, a TCR expression vector was designed and constructed, which can be used for various in vitro and in vivo applications, including identifying specific peptide sequences recognized by the TCR, manufacturing TCR-engineered T cells, studying T cell function, and screening potential immunotherapies. These findings are of great significance for the development of T cell-based cancer immunotherapies. Claims: 1 page; Description: 37 pages; Sequence Listing (electronic publication); Figures: 11 pages; CN 121464154 A 2026.02.03 CN 1 21 46 41 54 A
Claims
1. An immunoprotein comprising (a) a TCRβ chain variable domain (TCR-β domain) containing a complementarity-determining region (CDR) having the sequences SGHSA (SEQ ID NO:53), FRNQAP (SEQ ID NO:54), and ASSLDRGQDTQY (SEQ ID NO:55), (b) a TCRα chain variable domain (TCR-α domain) containing a CDR having the sequences TISGNEY (SEQ ID NO:56), GLQQN (SEQ ID NO:57), and ILRGTGGNNKLT (SEQ ID NO:58), or (c) both.
2. The immune protein of claim 1, wherein the immune protein comprises a T cell receptor (TCR), wherein the TCR comprises the TCR-β domain, the TCR-α domain, or both.
3. The immune protein according to claim 1 or 2, wherein the TCR-β domain has at least 75% sequence identity with SEQ ID NO: 51, and wherein the TCR-α domain has at least 75% sequence identity with SEQ ID NO:
52.
4. The immune protein according to claim 3, wherein the TCR-β domain comprises the sequence SEQ ID NO: 51, and wherein the TCR-α domain comprises the sequence SEQ ID NO:
52.
5. The immune protein according to any one of claims 1-4, wherein the immune protein targets hepatocellular carcinoma (HCC) antigen.
6. A pharmaceutical composition comprising the immune protein of any one of claims 1-5 and a pharmaceutically acceptable buffer, carrier, diluent or excipient.
7. A nucleic acid that encodes an immune protein according to any one of claims 1-5.
8. A vector comprising the nucleic acid of claim 7.
9. The vector according to claim 8, wherein the nucleic acid comprises an expression segment comprising coding regions in the following order: a signal sequence (e.g., fibL from silkworm moth), the TCR-β domain, the TCRβ constant region, a furin cleavage site, a flexible linker, T2A, the TCR-α domain, and the TCRα constant region.
10. A cell expressing the immune protein according to any one of claims 1-5.
11. The cell of claim 10, wherein the cell is a genetically modified T cell.
12. A cell population derived by amplifying the cells of claim 11.
13. A pharmaceutical composition comprising the cell population of claim 12 and a pharmaceutically acceptable buffer, carrier, diluent, or excipient.
14. A method for treating a subject suffering from a disease, symptom, or condition, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 6 or 13.
15. The method of claim 14, wherein the subject has HCC or has been identified as having an increased risk of developing HCC.
16. The method of claim 14 or 15, wherein the cell population is isolated from or derived from a cell amplification, and the cells are obtained from a subject who had the disease, condition, or illness prior to the introduction of the cells.
17. The method of claim 14 or 15, wherein the cell population is isolated from or derived from cell amplifications, and the cells are obtained from a healthy donor.
